Azeredo-da-Silva André Ferreira, Zanotto Bruna Stella, Kuwabara Yukie Sato, Mata Verónica Elizabeth
HTAnalyze Consulting and Training, Porto Alegre, Brazil.
National Institute for Health Technology Assessment (Instituto de Avaliacao de Tecnologias da Saude/Instituto Nacional de Ciencia e Tecnologia), Porto Alegre, Brazil.
Res Pract Thromb Haemost. 2022 Dec 9;7(1):100008. doi: 10.1016/j.rpth.2022.100008. eCollection 2023 Jan.
Various instruments have been used to assess health-related quality of life (HRQoL) in children and adolescents with hemophilia A.
We systematically reviewed the literature to summarize HRQoL measurement instruments and outcomes in this population.
MEDLINE, Embase, Cochrane CENTRAL, and LILACS databases were searched. Studies published from 2010 to 2021, reporting HRQoL assessed by generic or hemophilia-specific instruments in individuals aged 0 to 18 years were included. Two independent reviewers performed screening, selection, and data abstraction. Data were meta-analyzed using the generic inverse variance method with the random-effects model for single-arm studies reporting instrument-specific mean total HRQoL scores. Prespecified subgroup meta-analyses were performed. Heterogeneity among studies was assessed using the statistic.
Six instruments were identified in 29 studies meeting the following inclusion criteria: 4 generic instruments (PedsQL [5 studies], EQ-5D-3L [3 studies], KIDSCREEN-52 [1 study], and KINDL [1 study]) and 2 hemophilia-specific instruments (Haemo-QoL [17 studies] and CHO-KLAT [3 studies]). The overall risk of bias was moderate to low. There was a substantial variability in the primary outcome (mean total HRQoL score) among studies using the same instrument (Haemo-QoL), with scores ranging from 24.10 to 89.58 on a scale from 0 to 100 (higher scores indicating higher HRQoL). Meta-regression with 14 studies using the Haemo-QoL questionnaire demonstrated that 79.34% ( ) of the observed 94.67% total heterogeneity ( ) was explained by the proportion of patients receiving effective prophylactic treatment.
HRQoL assessment in young people with hemophilia A is heterogeneous and context specific. The proportion of patients on effective prophylactic treatment is positively correlated with HRQoL. The review protocol was registered prospectively with PROSPERO (CRD42021235453).
多种工具已被用于评估甲型血友病儿童和青少年的健康相关生活质量(HRQoL)。
我们系统回顾了文献,以总结该人群中HRQoL的测量工具和结果。
检索了MEDLINE、Embase、Cochrane CENTRAL和LILACS数据库。纳入2010年至2021年发表的研究,这些研究报告了使用通用或血友病特异性工具对0至18岁个体的HRQoL评估。两名独立评审员进行筛选、选择和数据提取。对于报告工具特定平均总HRQoL分数的单臂研究,使用通用逆方差法和随机效应模型对数据进行荟萃分析。进行了预先指定的亚组荟萃分析。使用 统计量评估研究之间的异质性。
在29项符合以下纳入标准的研究中确定了6种工具:4种通用工具(儿童生活质量量表[PedsQL,5项研究]、EQ-5D-3L[3项研究]、儿童筛查量表-52[KIDSCREEN-52,1项研究]和儿童生活质量指数[KINDL,1项研究])和2种血友病特异性工具(血友病生活质量量表[Haemo-QoL,17项研究]和儿童血友病生活质量评估工具[CHO-KLAT,3项研究])。总体偏倚风险为中到低。使用相同工具(Haemo-QoL)的研究之间,主要结局(平均总HRQoL分数)存在很大差异,分数范围为0至100分中的24.10至89.58分(分数越高表明HRQoL越高)。对14项使用Haemo-QoL问卷的研究进行的荟萃回归表明,接受有效预防性治疗的患者比例解释了观察到的94.67%的总异质性( )中的79.34%( )。
甲型血友病青少年的HRQoL评估具有异质性且因具体情况而异。接受有效预防性治疗的患者比例与HRQoL呈正相关。该综述方案已在PROSPERO(CRD42021235453)上进行了前瞻性注册。